Inventiva's Shareholders' Meeting Approves Key Resolutions

On July 2, 2026, Inventiva, a clinical-stage biopharmaceutical company, announced the results from their Combined Shareholders' Meeting held on June 30, 2026. The meeting took place at Hôtel Villa M in Paris and was led by CEO Andrew Obenshain. All proposed resolutions were adopted except for the 31st, which the Board had advised against. This resolution pertained to share capital increases for a company savings plan.

The meeting had significant participation, with a total quorum of 71.874%. Notably, compensation policies for corporate officers were endorsed as per the 2025 Universal Registration Document. The general assembly's voting saw substantial approval across ordinary and extraordinary resolutions, underscoring strong shareholder support for the company's strategic direction.